EGFR T790M resistance mutation in non small-cell lung carcinoma

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Epidermal growth factor receptor (EGFR) mutations drive lung cancer, with tyrosine kinase inhibitors (TKIs) showing high efficacy.
• Acquired resistance to EGFR-TKIs is a major clinical challenge, often mediated by specific mutations.
• The T790M mutation is a key mechanism of acquired resistance to EGFR-TKIs in lung cancer.

Purpose of the Study:

• To review methods for detecting the T790M gatekeeper mutation in EGFR.
• To explore the clinical applications of T790M detection in both treatment-naïve and resistant lung cancer patients.
• To highlight the significance of T790M in primary and acquired resistance to EGFR-TKIs.

Main Methods:

• Literature review of studies focusing on T790M mutation detection techniques.
• Analysis of data on the frequency of T790M detection using various methodologies.
• Evaluation of clinical studies investigating the role of T790M in EGFR-TKI treatment outcomes.

Main Results:

• The T790M mutation is identified as a primary event in some patients before drug exposure, with detection rates varying by method.
• T790M accounts for approximately half of acquired resistance cases to EGFR-TKIs.
• Different detection techniques yield varying frequencies of T790M identification.

Conclusions:

• Accurate detection of the T790M mutation is crucial for managing EGFR-mutated lung cancer.
• Understanding T790M status can guide treatment strategies in both TKI-naïve and resistant populations.
• Further research into sensitive T790M detection methods is warranted for improved patient care.